John Potthoff, Ph.D.
A respected veteran with nearly 28 years in the clinical research services industry, John Potthoff, Ph.D., has directed major business for a number of companies.
Potthoff’s career began with a series of executive roles involving increasing responsibility at PPD. After seven years, he left to become the founder and CEO of Tanistry, Inc., a contract research organization focused on the central nervous system. After selling Tanistry to INC Research in 2001, he joined INC Research, an 11-year career step that culminated in the role of COO.
Following his success at INC Research, Potthoff assumed the position of CEO at Theorem Clinical Research in 2011. In four years, he doubled its revenue, sales, backlog, and earnings before selling to Chiltern International in 2015.
Potthoff is NACD Directorship Certified and currently serves on the board of directors of Chembio (NASDAQ: CEMI) and previously served on the board of directors for Chiltern, Advarra, and Synteract.
Elligo Health Research®
Elligo Health Research® accelerates clinical trials through healthcare with access to over 150 million known patients and their HIPAA-compliant healthcare data, our IntElligo® Research Stack technology, and our PatientSelect identification and engagement model. Coupled with the largest Known Patient Access Network, Elligo’s Site Solutions enable healthcare practices and research sites to participate in clinical trials. By adaptive engagement of known patients and physicians, we accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products.